Key Inclusion Criteria:

          -  Histologically confirmed large B-cell lymphoma

          -  Chemotherapy-refractory disease, defined as one or more of the following:

               -  No response to first-line therapy (primary refractory disease)

               -  No response to second or greater lines of therapy OR

               -  Refractory after autologous stem cell transplant (ASCT)

          -  At least 1 measureable lesion according to the Lugano Classification (Cheson 2014).

          -  Individuals must have received adequate prior therapy, including at a minimum:

               -  Anti-CD20 monoclonal antibody

               -  An anthracycline-containing chemotherapy regimen

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate renal, hepatic, pulmonary, and cardiac function

        Key Exclusion Criteria:

          -  Known CD19 negative or CD20 negative tumor

          -  History of Richter's transformation of Chronic Lymphocytic Leukemia (CLL)

          -  Prior CAR therapy or other genetically modified T-cell therapy

          -  Prior organ transplantation including prior allogeneic stem cell transplant (SCT)

          -  Prior CD19 targeted therapy

          -  Clinically significant infection or cardiopulmonary disease

          -  Presence of any in-dwelling lines or drains (dedicated central venous access catheters
             allowed)

          -  History or presence of central nervous system (CNS) lymphoma or nonmalignant CNS
             disorder or cerebrospinal fluid (CSF) malignant cells or brain metastases

          -  History of autoimmune disease

          -  History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last 6
             months

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.